two

Lab Automation Networks Proliferating

Although it may still seem radically innovative in the context of many clinical laboratories, automated production in the manufacturing sector had been the norm for many years. In automobile assembly, for example, automated lines fabricate sub-assemblies and entire vehicles with only occasional human oversight. The result has been vastly improved products, far fewer defects, and significant p...

NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

EAST WINDSOR, N.J.--(BUSINESS WIRE)--July 9, 2007 - NexMed, Inc.(NASDAQ: NEXM), a developer of innovative transdermal treatmentsbased on the NexACT(R) drug delivery technology, today announcedthat Novartis Pharma AG has completed patient enrollment for PhaseIII clinical trials for NM100060, a topical treatment foronychomycosis (nail fungus). Pursuant to the terms of the licensingagreement w...

Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycin's First of Two Phase 3 Pneumonia Trials

CHICAGO, June 29, 2007 /PRNewswire-FirstCall/ -- Advanced LifeSciences Holdings, Inc. , today announced that it will host aconference call and live webcast at 10:00 am (EDT) on Monday, July2, 2007 to discuss data from Trial CL-06, the first of two pivotalPhase 3 clinical trials designed to assess the safety andeffectiveness of cethromycin, a novel once-a-day antibiotic, forthe treatment...

Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target

OSS, the Netherlands, June 27, 2007-Organon, the humanhealthcare business unit of Akzo Nobel, announced today that twoout of three Phase III clinical trials with corifollitropin alfa(Org 36286), a new long-acting fertility hormone, have reachedtheir randomization target. Corifollitropin alfa is a new recombinant fertility hormone. It isthe first of a new class of gonadotropi...

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpreliminary results from two open-label, multi-center Phase 2clinical trials supporting the potential use of Xcytrin(R)(motexafin gadolinium) Injection, the company's lead productcandidate, in combination with Alimta(R) (pemetrexed) and incombination with Taxotere(R) (docetaxel...

Publication Confirms that EpCAM, the Target for Two of Micromet's Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers

BETHESDA, Md., June 26, 2007 /PRNewswire-FirstCall/ -- Micromet,Inc. , a biopharmaceutical company focusing on the development ofnovel, proprietary antibody-based products for cancer, inflammatoryand autoimmune diseases, announced that a study published recentlyin the Proceedings of the National Academy of Sciences (1) supportsthe findings of several other studies that EpCAM (CD326), whic...

Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials

BRANFORD, Conn.--(BUSINESS WIRE)--Jun 25, 2007 - NeurogenCorporation (Nasdaq: NRGN) today announced positive top-lineresults from two dose-ranging, Phase 2b clinical trials in chronicinsomnia patients with the Company's proprietary insomnia agent,NG2-73, an alpha-3 preferring GABA(A) partial agonist. Multipleformulations were studied in each trial to determine the bestprofile for rapidity o...

New Report 'Looking at Chiral Technologies' Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals

DUBLIN, Ireland--(BUSINESS WIRE)--Jun 21, 2007 - Research andMarkets (http://www.researchandmarkets.com/reports/c60415) hasannounced the addition of Looking at Chiral Technologies to theiroffering. The advancements in molecular research and continued untiringefforts of the research industry to develop better more preciselyapplicable Pharmaceuticals as well as agro compounds would have not...

Remicade Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation

Findings from the ASSERT Trial Presented at EULAR BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ -- Datapresented today at the European League Against Rheumatism (EULAR)Annual European Congress of Rheumatology showed that patients withankylosing spondylitis (AS) who received REMICADE(R) (infliximab)over two years experienced significant improvement in spinalmobility. In addition,...

Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--Jun 13, 2007 - NeurogenCorporation (Nasdaq: NRGN) today announced that data from previousPhase 1 and Phase 2a clinical studies for NG2-73, the Company'slead compound for the treatment of insomnia, were presented in twosessions at the SLEEP 2007 Annual Meeting of the AssociatedProfessional Sleep Societies (APSS) in Minneapolis, Minnesota. TwoPhase 2b clinica...

Inspire Announces Presentations at Two European Scientific Conferences

DURHAM, N.C.--(BUSINESS WIRE)--Jun 12, 2007 - InspirePharmaceuticals, Inc. (NASDAQ: ISPH) announced today thatscientists and collaborators related to Inspire will presentinformation at the XXVI Congress of the European Academy ofAllergology and Clinical Immunology (EAACI) being held June 9-13,2007 in Goteborg, Sweden and at the 30th European Cystic FibrosisSociety (ECFS) Conference being he...

Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

Interim Data from Phase 1 Clinical Trial of SNS-595 in AcuteLeukemia Demonstrates Additional Clinical Activity SOUTH SAN FRANCISCO, Calif., June 11, 2007/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. presentedpositive data from clinical studies of two of the company'santi-cancer product candidates, SNS-595 and SNS-032, at the 12thCongress of the European Hematology Association (E...

Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Jun 6, 2007 - SavientPharmaceuticals, Inc. (NASDAQ: SVNT) announced today that twoabstracts exploring Phase 2 Puricase(R) (PEG-uricase) data andquality of life in treatment-failure gout patients will bepresented at the European League Against Rheumatism (EULAR) 2007Annual Congress taking place June 13 - 16th in Barcelona, Spain.Puricase is a PEGylated...

NovaDel Announces Positive Data from Two Studies Comparing Zolpidem Oral Spray to Ambien Tablets

FLEMINGTON, N.J.--(BUSINESS WIRE)--Jun 5, 2007 - NovaDel PharmaInc. (AMEX: NVD), a specialty pharmaceutical company developingoral spray formulations for a broad range of marketed treatments,today announced that its two clinical studies comparing zolpidemoral spray with zolpidem tablets have met their primarypharmacokinetic (PK), pharmacodynamic (PD) and safety objectives.Zolpidem tablets a...

Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting

* Preclinical study evaluating a clinically relevant model ofnormal human skin found that Menadione was the only agent capableof abrogating the cytotoxic effect of erlotinib * Phase I singleagent Marqibo(r) showed OPTISOME(tm) agent was generally welltolerated in metastatic melanoma patients with an adverse eventprofile similar to conventional vincristine SOUTH SAN FRANCISCO, Calif...

Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up

Separate Survey Underscores Impact of Disease on Work Status andProductivity WASHINGTON, May 23, 2007 /PRNewswire-FirstCall/ -- Findingspresented today at Digestive Disease Week(R) 2007 (DDW), fromlong-term extensions of the ACT trials (Active Ulcerative Colitis 1& 2) show that subjects with moderately to severely activeulcerative colitis (UC) who had responded to REMICADE(R)(inflixi...

Inovio Biomedical's Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials

SAN DIEGO--(BUSINESS WIRE)--May 17, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA-basedvaccines for cancers and infectious diseases and a novelalternative to surgery to treat localized cancers, announced todaythat partners of the company will present new interim data from twophase I clinical trials of plasmid-based immunotherapies usingInovio's electropor...

Lux Biosciences' Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007

JERSEY CITY, N.J.--(BUSINESS WIRE)--May 4, 2007 - Lux Biosciences,Inc., a privately held biotechnology company specialized in thefield of ophthalmic diseases, announced today that the company'snext-generation calcineurin inhibitor, LX211, is the subject of twopresentations at the Association for Research in Vision andOphthalmology (ARVO) annual meeting, being held May 6-10 in FortLauderdale...

Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients

KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data havedemonstrated that relapsing-remitting multiple sclerosis (RRMS)patients treated with COPAXONE(R) (glatiramer acetate injection)following brief immunosuppression with mitoxantrone experienced a90 percent reduction in magnetic resonance imaging (MRI)-monitoreddisease activity compared to their baseline. These benefits wereachieved...

Pluristem to Present Two Scientific Posters at the International Society for Cellular Therapy

NEW YORK--(BUSINESS WIRE)--May 2, 2007 - Pluristem Life Systems,Inc. (OTCBB:PLRS), a cell therapy Company dedicated to thecommercialization of products for a variety of indications,announced today that it will present two scientific posters at the13th Annual Meeting of the International Society for CellularTherapy (ICST), June 24-27, 2007 in Sydney Australia. Pluristem CEO and Chairman, M...

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN

Interim analysis of Phase 2 comparative study showed significantresults in favor of alemtuzumab versus Rebif CAMBRIDGE, Mass. and WAYNE, N.J., May 02, 2007/PRNewswire-FirstCall/ -- Genzyme Corporation and Bayer HealthCarePharmaceutical today announced detailed interim results from theCAMMS223 Phase 2 study. This interim analysis of all patient datathrough at least twenty-four months from...

Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh to be Presented at European Vascular Symposium

STRASBOURG, France and VANCOUVER, April 26, 2007/PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. , a globalspecialty pharmaceutical and medical device company, announced thatthe two-year data from its European pivotal trial examining theVascular Wrap(TM) Paclitaxel-Eluting Mesh ("Vascular Wrap(TM)")will be presented today at a scientific forum in Europe. Thetwo-year study examine...

Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntington's Disease

Conference Call Begins Today at 11:00 a.m. Eastern Time LONDON, April 24, 2007 /PRNewswire-FirstCall/ -- AmarinCorporation plc ("Amarin" or the "Company") today announcestop-line results from its two Phase III clinical trials of Miraxionto treat Huntington's disease (HD). The Company conducted two PhaseIII double-blind, placebo-controlled studies in which HD patientswere randomized to rec...

Novelos Therapeutics and MUSC Present Two Posters at AACR 2007 Annual Meeting

NEWTON, Mass.--(BUSINESS WIRE)--Apr 16, 2007 - NovelosTherapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical companyfocused on the development of therapeutics to treat cancer andhepatitis, today announced that the company, in collaboration withDr. Kenneth Tew and Dr. Danyelle Townsend of the Medical Universityof South Carolina (MUSC), is making two poster presentations at theongoing American...

Gentium's Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting

VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Apr 13, 2007 -Gentium, S.p.A. (NASDAQ:GENT) (the "Company") today reported thatits lead investigational product, Defibrotide, will be the subjectof two poster presentations at the American Association for CancerResearch's (AACR) Annual Meeting being held at the Los AngelesConference Center in Los Angeles, California, from April 14-18,2007. On...

Advanced Magnetics Announces Positive Results from Two Additional Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement Therapeutic

CAMBRIDGE, Mass., April 11, 2007 /PRNewswire-FirstCall/ --Advanced Magnetics today announced positive results from twoadditional Phase III clinical trials of ferumoxytol as anintravenous (IV) iron replacement therapeutic that are beingpresented today at approximately 6:00 pm EDT as posters at theNational Kidney Foundation's Spring Clinical Meeting in Orlando,Florida. These posters are av...

Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver

Additional Preclinical Data Presented on Valopicitabine Combinedwith an Investigational Protease Inhibitor BARCELONA, Spain, April 12, 2007 /PRNewswire-FirstCall/ --Idenix Pharmaceuticals, Inc. today announced results from two phaseIIb studies of the novel combination of valopicitabine (NM283) andpegylated interferon alfa-2a (Pegasys(R)) in both treatment-naiveand treatment- experienced p...

Scientific Results Presented At ECCMID Demonstrate Well- Differentiated Profile of Basilea's Two Phase III Anti- infective Compounds

BASEL, Switzerland, April 3, 2007 (PRIME NEWSWIRE) -- New datapresented at ECCMID highlight the microbiological andpharmacokinetic profiles of Basilea's (SWX:BSLN) two late-stagedrug candidates ceftobiprole and isavuconazole. Studies reportedboth for ceftobiprole, the first anti-MRSA broad-spectrumcephalosporin in late-stage development, and for isavuconazole, anovel azole for the treatm...

Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show

NEW ORLEANS--(BUSINESS WIRE)--Mar 27, 2007 - Pfizer announced todaythat Lipitor(R) (atorvastatin calcium) Tablets (80 mg) loweredhospitalization costs by significantly reducing the risk ofcardiovascular events in patients with heart disease, according totwo separate economic analyses. The data were presented at theannual meeting of the American College of Cardiology. "One of these analyse...

Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke

EXACT and CAPTURE 2 Findings Suggest Improved Outcomes in CarotidArtery Stenting ABBOTT PARK, Ill., March 26, 2007 /PRNewswire-FirstCall/ --Positive 30-day results from two Abbott studies confirm thatcarotid stenting can be performed with positive results byphysicians with a variety of background experience in real-world(non-clinical trial) settings in patients who are not favorablecandi...

Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stent's Positive Clinical Profile

MINNEAPOLIS--(BUSINESS WIRE)--Mar 26, 2007 - Two-year results fromthe Medtronic (MDT:NYSE) ENDEAVOR III trial confirm the positiveclinical profile of the Endeavor(R) drug-eluting coronary stent andbring to nearly 1,300 the number of Endeavor patients who have atleast two years of follow-up. Significantly, among those 1,300Endeavor patients, there have been no reported cases of late stentthr...

Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- A large patientregistry of "real world" uses for the CYPHER(R) Sirolimus-elutingCoronary Stent reported favorable safety and efficacy outcomes attwo-year follow-up, according to clinical investigators at the ofCardiology's 56th Annual Scientific Session (ACC.07). The MATRIX Registry is a prospective, single-arm study designedto evaluate t...

Two New Imaging Studies Show Higher Dose Lipitor Stopped the Progression of Atherosclerosis

NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Pfizer said today thatresults from two new imaging trials showed that higher dose Lipitorstopped the progression of atherosclerosis in patients withcoronary heart disease or familial hypercholesterolemia (FH). Thetrials, which were designed to investigate the efficacy of theformer investigational compound torcetrapib in combination withLipitor co...